RxDoctor Payments DataLook up a doctor →

Diane Hearn, NP

Nurse Practitioner · Bethesda, MDNPI 1023370921

Payments from drug & device makers

$6,761in general payments, 2019–2025

Across 254 payments — averaging $26.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$858
  • Novartis$540
  • Merck$374
  • AstraZeneca$345
  • Incyte Corporation$287
  • Takeda Pharmaceuticals U.S.A., Inc.$287
  • plus $4K from 54 others

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Johnson & Johnson(2 entities)27$858
Novartis23$540
Merck18$374
AstraZeneca(2 entities)15$345
Incyte Corporation8$287
Takeda Pharmaceuticals U.S.A., Inc.9$287
AbbVie10$275
Astellas Pharma US Inc8$196
Rigel Pharmaceuticals, Inc.5$194
Seagen Inc.7$191
Bristol Myers Squibb8$182
Pharmacyclics LLC, An Abbvie Company7$173
Regeneron Healthcare Solutions, Inc.5$148
Lilly USA, LLC3$147
Pfizer6$141
Exelixis Inc.6$130
Daiichi Sankyo Inc.5$128
Genentech USA, Inc.2$125
Sanofi4$120
Amgen6$111
Global Blood Therapeutics, Inc.4$97
Pharmacosmos Therapeutics Inc.3$84
Myovant Sciences Inc.2$80
Sanofi-aventis U.S. LLC1$77
AVEO Pharmaceuticals, Inc.3$74
Ipsen Biopharmaceuticals, Inc3$66
Taiho Oncology, Inc.3$66
Gilead(2 entities)3$64
Puma Biotechnology, Inc.3$62
Pharmaessentia USA Corporation2$61
GSK2$61
EMD Serono, Inc.2$60
GE HealthCare1$60
Bayer3$57
Myriad Genetic Laboratories, Inc.3$52
Boehringer Ingelheim2$50
Tactile Systems Technology Inc1$47
Sobi, Inc2$46
Kyowa Kirin, Inc.2$43
Eisai Inc.2$43
Beigene USA, Inc.2$40
Acrotech Biopharma Inc.2$40
Iovance Biotherapeutics, Inc.1$39
ADC Therapeutics America, Inc.2$36
Mirati Therapeutics, Inc.1$36
Caris MPI, Inc.1$30
Tempus AI, Inc1$29
Beone Medicines USA, Inc.1$29
Clovis Oncology, Inc.1$25
Amneal Pharmaceuticals LLC1$25
Immunocore Limited1$25
EUSA Pharma (US) LLC1$24
Blueprint Medicines Corporation1$21
Tersera Therapeutics LLC1$21
Array Biopharma Inc1$21
Deciphera Pharmaceuticals Inc.1$20
Karyopharm Therapeutics Inc.1$20
Alnylam Pharmaceuticals Inc.1$20
Stemline Therapeutics Inc.1$18
Servier Pharmaceuticals LLC1$17

How this compares

$6,761 in reported general payments places this provider in the 95th percentile of 1,562 nurse practitioner providers in Maryland.

See all nurse practitioner providers in Maryland →

Medicare billing

Part B allowed, 2024
$3,631
Medicare patients
40
Services billed
44

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other nurse practitioner in Bethesda

See the full list for Maryland →

Where these figures come from

Is this you, or does something look wrong? →